Abstract：Objective To summarize the outcomes and prognostic factors in esophageal cancer (EC) patients treated with three-dimensional radiotherapy (3DCRT and IMRT). Methods Five hundred ninety-two EC patients received three-dimensional radiotherapy (123 with 3DCRT, 469 with IMRT) in our hospital from January 2002 to March 2012. Three hundred and sixty patients received radiotherapy alone and 232 patients received radiotherapy and chemotherapy. The median radiotherapy dose was 60 Gy. Concurrent chemotherapy was used with paclitaxel plus platinum (weekly schedule). Sequential chemotherapy was used with paclitaxel or fluorouracil plus platinum (3-week schedule). The Kaplan-Meier method was used to calculate overall survival (OS) and progression-free survival (PFS), and the log-rank test was used for survival difference analysis and univariate prognostic analysis. The Cox regression model was used for multivariate prognostic analysis. Results The numbers of samples at 3 and 5 years were 142 and 53, respectively. The 1-year OS and PFS were 65.3% and 52.1%, respectively;the 3-year OS and PFS were 34.0% and 28.0%, respectively;the 5-year OS and PFS were 23.5% and 19.6%, respectively. The median OS was 20 months (95% CI:17.9-22.1 months) and the median PFS was 14 months (95% CI:11.8-16.2 months). Univariate analysis indicated that sex, N stage, M stage, TNM stage, radiotherapy dose, weight loss before treatment, smoking, and drinking were prognostic factors for OS and PFS (P=0.002 and 0.000,0.000 and 0.000,0.001 and 0.000,0.000 and 0.000,0.000 and 0.000,0.024 and 0.026,0.009 and 0.005,0.000 and 0.000). Multivariate analysis showed that TNM stage, radiotherapy dose, and sex were prognostic factors for OS and PFS (P=0.000 and 0.000,0.000 and 0.001,0.036 and 0.027). Conclusions The outcomes of EC patients treated with three-dimensional radiotherapy alone or combined with chemotherapy are promising. Early TNM stage, high radiotherapy dose, and female sex are independently associated with better OS and PFS.
Tan Lijun,Liu Xiao,Xiao Zefen et al. Analysis of outcomes and prognostic factors in 592 esophageal cancer patients treated with three-dimensional radiotherapy[J]. Chinese Journal of Radiation Oncology, 2015, 24(1): 10-14.
[1] 肖泽芬.食管癌[A]//殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].4版.北京:中国协和医科大学出版社,2008:546-573. [2] 殷蔚伯,张力军,杨宗贻,等.放射治疗食管癌3798例临床分析[J].中华肿瘤杂志,1980,2(3):216-220. [3] 上海市肿瘤医院放射治疗科.1034例食管癌放射治疗临床分析[J].肿瘤防治研究,1978,6(4):46-51. [4] 肖泽芬,章众,张红志,等.用三维治疗计划系统评估食管癌常规放射治疗中肿瘤剂量的分布[J].中华放射肿瘤学杂志,2004,13(4):273-277. [5] Sobin LH, Wittekind CH. TNM classification of malignant tumours[J].New York:Wildy-Liss,2002. [6] 施学辉,吴广丰,姚伟强,等.食管癌放射治疗照射野大小的预测[J].中华放射肿瘤学杂志,1992,1(4):219-222. [7] 肖泽芬,章众,王铸,等.食管癌照射野合理使用的初步探讨[J].中华放射肿瘤学杂志,1999,8(1):27-31. [8] 蒋杰,王奇峰,肖泽芬,等.132例食管癌三维适形放疗的疗效分析[J].中华放射肿瘤学杂志,2009,18(1):47-51. [9] Zhao KL, Ma JB, Liu G, et al. Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma:is elective nodal irradiation necessary?[J]. Int J Radiat Oncol Biol Phys,2010,76(2):446-451.DOI:10.1016/j. ijrobp.2009.02.078. [10] 孔洁,李晓宁,韩春,等.792例食管癌三维技术放疗的疗效分析[J].中华放射肿瘤学杂志,2012,21(5):421-424.DOI:10.3760/cma.j.issn.1004-4221.2012.05.007. [11] Lin SH, Wang L, Myles B, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer[J]. Int J Radiat Oncol Biol Phys,2012,84(5):1078-1085.DOI:10.1016/j. ijrobp.2012.02.015. [12] Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123(Radiation Therapy Oncology Group 94-05) phase Ⅲ trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy[J]. J Clin Oncol,2002,20(5):1167-1174. [13] Ohtake S, Asakawa H, Koyama K, et al. Analysis of 5-year survivors of esophageal cancer treated with radiation and chemotherapy[J]. Gan No Rinsho,1987,33(3):253-257. [14] Sun DR.Ten-year follow-up of esophageal cancer treated by radical radiation therapy:analysis of 869 patients[J]. Int J Radiat Oncol Bilo Phys,1989,16(2):329-334. [15] Semrau R, Herzog SL, Vallbhmer D, et al. Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer[J]. Dis Esophagus,2012,25(6):545-554.DOI:10.1111/j. 1442-2050.2011.01286.x. [16] Rice TW, Rusch VW, Appeerson-Hansen C, et al. Worldwide esophageal cancer collaboration[J]. Dis Esophagus,2009,22(1):1-8.DOI:10.1111/j.1442-2050.2008.00901.x. [17] 刘晓,王贵齐,贺舜,等.探讨非手术食管癌临床分期有效性与预测预后价值[J].中华放射肿瘤学杂志,2014,23(1):17-22.DOI:10.3760/cma.j.issn.1004-4221.2014.01.005. [18] Hareyama M, Sakurai T, Nishio M, et al. Radiotherapy treatment of esophageal carcinoma-analysis of 5-year survival[J]. Gan No Rinsho,1984,30(8):885-890. [19] Cooper, JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group[J]. JAMA,1999,281(17):1623-1627.
2015, Vol. 24 
